Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2023-05-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物自愿披露关于9MW3811注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding the approval of a clinical trial for their drug 9MW3811 injection. It contains no financial data, no financial statements, and no discussion of financial results or management analysis. It is an announcement of a regulatory approval related to drug clinical trials, not a financial report or management report. The document is short (1498 characters) and serves as a formal public announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-24 Chinese
迈威生物自愿披露关于注射用7MW3711获得药物临床试验申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company about receiving a clinical trial application acceptance notice from the National Medical Products Administration. It details the drug's characteristics, the technology platform, and risk warnings. The document is an official announcement about a regulatory milestone related to drug development, not a financial report, management change, or shareholder meeting material. It does not contain financial statements or earnings data. It is a regulatory announcement about a clinical trial acceptance, fitting best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-05-10 Chinese
迈威生物自愿披露关于9MW3911注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving approval for a clinical trial of a drug (9MW3911 injection). It includes details about the drug, the approval notice, and risk warnings. The document is short (1126 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event related to drug development, not a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-09 Chinese
迈威生物2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of the company 迈威（上海）生物科技股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including approval of the 2022 annual report, financial statements, profit distribution, board and supervisory committee elections, and other governance matters. The document also contains legal attestations from lawyers confirming the validity of the meeting and voting procedures. This type of document is a formal announcement of the AGM meeting resolutions and voting results, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the full annual report itself, nor a proxy statement or management report. The length and detail confirm it is not a brief announcement or a simple notice but a full voting results announcement from the AGM.
2023-04-27 Chinese
北京植德（上海）律师事务所关于迈威（上海）生物科技股份有限公司2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Maiwei (Shanghai) Biotechnology Co., Ltd. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the voting results on various resolutions including approval of the 2022 annual report, financial statements, profit distribution, budget, board and supervisory reports, auditor appointment, remuneration, and board and supervisory elections. The document does not contain the actual annual report or financial statements but rather certifies the legality and validity of the AGM process and voting results. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2023-04-27 Chinese
迈威生物第一届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Maiwei (Shanghai) Biotechnology Co., Ltd. It reports on the meeting held on April 24, 2023, where the Supervisory Board reviewed and approved the company's 2023 first quarter report and a financing proposal. The document does not contain the actual quarterly report or detailed financial data but rather the Supervisory Board's approval of the report and financing matters. It is a formal announcement of board/management decisions and approvals, not the report itself or a detailed financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short (809 characters), and it is not a report publication announcement or certification letter. Hence, the classification is MANG with high confidence.
2023-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.